United States: Senate HELP Committee Convenes Third And Final Cures Markup

Last Updated: April 14 2016
Article by Eli Greenspan

This morning the Senate Committee on Health, Education, Labor, and Pensions (HELP) will hold its third and final markup for its biomedical innovations package. This package is a compliment to the House-passed 21st Century Cures Act, which the House passed in July of 2015. The previous two hearings HELP held on this issue have gone relatively smoothly, with the committee agreeing to move the legislation largely by voice vote. However, a number of unresolved issues remain and hold the potential to send the entire package up in flames.

While this hearing should be no different when it comes to the legislation being discussed, this will be the committee members final opportunity to offer amendments or raise issues before the legislation moves to the Senate floor for consideration. Issues relating to drug pricing and mandatory funding for NIH will likely be discussed at length today. In addition, funding for these measures, including the Administration's Precision Medicine Initiative, will be up for debate.

Here is a preview of the legislation to be considered:

S. 2700, the FDA and NIH Workforce Authorities Modernization Act

S. 2700 would update the workforce authorizing provisions relating to the National Institutes of Health and the Food and Drug Administration. Specifically, this legislation would enable the FDA to more fully participate in the Biomedical Research Service to attract more qualified scientists to its ranks. Currently, the Biomedical Research Service is used primarily by NIH. This legislation would also increase the number of people eligible for the Biomedical Research Service at both agencies.

This legislation would also:

  • Establish a pilot program to test the best ways to boost communication and information sharing between different centers at the FDA.
  • Strengthen policies that would enable FDA and NIH scientists to attend scientific conferences so they can stay informed on the latest developments and achievements in science.
  • Make it easier for FDA scientists and regulators to partner and collaborate with those in the private sector.
  • Exempt NIH research from relying on the voluntary data collection from the Paperwork Reduction Act.

S. 185, the Promise for Antibiotics and Therapeutics for Health (PATH) Act

The PATH Act would enable the FDA to expedite an antibacterial drug's approval on the condition that it is for an identifiable, limited patient population. Additionally, the drug would have to treat a serious or life-threatening condition and address unmet needs. The bill would also require the drug's label to include a special designation indicating its intended use in limited, high-risk populations.

S. 185 was introduced by Senator Orrin Hatch (R-UT) with five bipartisan co-sponsors.

S. 2713, the Advancing Precision Medicine Act of 2016

This legislation would provide the Secretary of HHS with processes for the implementation of the Precision Medicine Initiative. The responsibilities of HHS would include:

  • Developing a network of scientists to assist in carrying out the Initiative.
  • Developing new approaches for addressing scientific, medical, and public health issues, among others.
  • Applying genomic technologies to provide data on the molecular basis of disease.
  • Collecting information voluntarily provided by a diverse cohort of individuals.
  • Coordinating with the Secretary of Energy, the private sector, and others to identify and address the advanced super computing needs of the Initiative.

Here is the full text of the legislation for more information.

S. ____, the Promoting Biomedical Research and Public Health for Patients Act

This legislation would update reporting requirements across NIH to ensure that Congress receives a more cohesive and comprehensive report of the agency every three years. It would establish processes which would require directors at the agency's 27 institutes and centers to be reappointed every five years to allow for evaluation and increased accountability.

This legislation would also require NIH to evaluate reporting requirements on researchers and to eliminate requirements seen as duplicative or irregular. It would also direct the Office of Management and Budget to establish a board to look at the impacts of federal regulation on research and recommend improvements. Lastly, it would allow universities and others participating in the National Center for Advancing Translational Sciences (NCATS) supported clinical research to conduct later-stage clinical trials in an effort to foster greater private investment in public biomedical research.

S. ____, the NIH Strategic Plan and Inclusion in Clinical Research Act

This legislation would promote the inclusion of minorities in clinical research by requiring NIH, when developing its strategic plan, to assemble accurate data on public health burdens, and on progress to reduce health disparities among women, minorities, and certain age groups. This data would then be used to assess research priorities. Additionally, this legislation would make it easier for individual centers and institutes to encourage research which would achieve the goals of NIH relating to minority health and addressing health disparities. This legislation would also establish a task force on research specific to women, with a focus on pregnant and lactating women.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions